Health Catalyst CEO Sells 70,455 Shares to Cover Taxes – Stock Impact Is Minimal

Corporate News – Insider Trading Activity at Health Catalyst

Health Catalyst Inc. (NASDAQ: HCAT) announced that its chief executive officer, Albert Benjamin, executed a sell‑to‑cover transaction on March 10 2026. The CEO sold 70,455 shares of common stock at $1.85 per share, a price that slightly exceeded the closing market price of $1.79 for the day. The transaction was performed to satisfy tax withholding obligations on restricted units that had vested and is not indicative of a strategic divestiture. Benjamin’s net ownership of the company remains unchanged at 1,457,978 shares after the sale.

Transaction Context

• The March 10 sale is part of a series of routine sell‑to‑cover transactions that have characterized Benjamin’s recent SEC filings.
• Previous transactions include:
• 4,966 shares sold on March 2, 2026
• 13,304 shares sold on February 26, 2026
• 930,000 shares purchased earlier in February, partially offset by a 38,833‑share purchase on the same day.
• The CEO’s pattern of activity reflects the mechanics of an incentive plan for executives with significant restricted‑unit balances.

Market Impact and Investor Interpretation

1. Neutral Effect on Stock Price

• The March 10 transaction involved a modest volume relative to the company’s daily trading activity and was executed near market close, minimizing potential market impact.
• Health Catalyst’s share price has been in a steep downtrend: down 10 % in the month, 59 % year‑to‑date, and trading near its 52‑week low of $1.56.

2. Fundamentals Remain Weak

• The company’s earnings‑per‑share ratio remains negative (–1.12), and operating results continue to show losses.
• Despite the sale, there is no evidence that the CEO is signaling a loss of confidence.

3. Insider Activity as a Sentiment Indicator

• In February, insiders (Benjamin, Landry, and Alger) sold over 140,000 shares collectively.
• Some executives purchased significant stakes in December 2025, suggesting that at least a subset of insiders still believe in the company’s long‑term upside.

4. Capital‑Raising Context

• Health Catalyst has filed a new S‑8 registration statement to issue over four million shares, indicating ongoing capital‑raising ambitions.
• An 8‑K filing disclosed modest revenue decline but improved adjusted EBITDA, underscoring the company’s focus on operational efficiency.

Historical Trading Profile of Albert Benjamin

• Benjamin’s trading volume is relatively low compared to other executives, reflecting a preference for maintaining a sizable position while avoiding significant market impact.
• Timing of trades—often at market close—suggests a focus on minimizing trading costs and avoiding the appearance of market timing.

Implications for Investors

• No Immediate Strategic Pivot: The CEO’s activity is primarily regulatory and tax‑related.
• Watch for Future Insider Purchases: A shift in insider buying behavior could signal changing sentiment, particularly if the stock recovers from its current low.
• Assess Operational Metrics: Investors should consider both the company’s financial performance and the timing of insider trades when evaluating potential upside or downside risk.

Summary Table

All figures are derived from the most recent SEC filings available as of March 2026.